The Center for Regenerative Medicine (CRM) is a research unit that provides viable alternative or adjunct cutting-edge therapy for chronic, autoimmune, and degenerative diseases such as cancer, multiple sclerosis, ischemic cardiomyopathy, and osteoarthritis. The center is accredited by the Philippines’ Department of Health (DOH) as “a facility that may engage in human stem cell or cellular therapy” in accordance with Administrative Order (AO) No. 2013-012. The center’s own laboratory is at par with the United States Food and Drug Administration (FDA) sterility standard (ISO Class 5 Clean Room), ensuring cell purity (at least 90 to 95 percent) and cell viability of the product. It adheres to global standards in cellular therapeutics practice, training, and research, and staffed by experienced scientists dedicated to healthcare excellence.
The center has collaborated with the Department of Science and Technology (DOST) – Philippine Council for Health and Research Development (PCHRDS) for the study Evaluation of the Safety and Efficacy of Intramuscular Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells for Diabetic Food Ulceration; to be a service provider for the isolation and expansion of umbilical cord tissue of a Philippine cord blood processing and cryopreservation facility.
The center and its local facility partner are embarking towards a collaborative research in using cord blood and cord tissue as a source for cellular therapy.
Directors of the Center for Regenerative Medicine:
Joey D. Borromeo, MD